Overview
Allogeneic stem cell transplantation with a focus on the use of umbilical cord blood grafts; Allogenic stem cell transplantation for Sickle Cell Disease; Prevention of acute and chronic graft versus host disease; Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation.
Current Appointments & Affiliations
Professor of Medicine
·
2016 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Publications
Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel.
Journal Article Br J Haematol · January 19, 2026 Full text Link to item CiteExploring Perspectives on Feasibility, Challenges, and Support Needs for Chlorhexidine Gluconate (CHG) Bathing in the Outpatient Setting for Hematopoietic Cell Transplant Recipients: A Qualitative Study.
Journal Article Transplant Cell Ther · January 2026 BACKGROUND: Chlorhexidine gluconate (CHG) bathing is recommended for infection prevention in hematopoietic cell transplantation (HCT) patients. As more centers transition HCT care to outpatient settings, understanding patients' perceptions of CHG bathing f ... Full text Link to item CiteAllogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR.
Journal Article Transplant Cell Ther · December 2025 Allogeneic hematopoietic cell transplantation (HCT) remains a curative therapy for many patients with hematologic malignancies, bone marrow failure syndromes, inborn errors of immunity and metabolic disorders. Current donor selection strategies typically p ... Full text Link to item CiteRecent Grants
Blood and Marrow Transplant Clinical Trials Network
Clinical TrialPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2001 - 2031Deciphera DCC-3014-02-001: A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Clinical TrialPrincipal Investigator · Awarded by Deciphera Pharmaceuticals, LLC · 2025 - 2030A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030View All Grants
Education, Training & Certifications
Rush University ·
1992
M.D.